Categories Earnings, Technology

Lumentum Holdings fall on Q2 earnings miss

Lumentum Holdings (LITE), which makes optical components and modules for communication networks, reported a 7.6% decline in second-quarter net revenue to $373.7 million. The top line surpassed the street projection of $356.41 million.

Earnings, adjusted for one-time items, were $1.15 per share, one cent shy of what analysts were expecting. On a reported basis, net income attributable to common shareholders plunged to 8 cents per share from $3.05 per share in the same quarter last year.

LITE shares fell 5.3% during pre-market trading post the earnings announcement. The stock has gained 16% in the trailing 12 months.

For Q3, the company expects net revenue in the range of $420 million to $440 million. Adjusted earnings per share is projected to be between $0.76 to $0.94 during this period.

CEO Alan Lowe said, “Strength in Telecom demand is expected to continue in the third quarter, counter to historical seasonality. Second quarter 3D sensing revenue came in as expected, and we continue to make progress with new design wins with new and existing customers.”

Read: Earnings preview: What’s on the plate for Chipotle Mexican Grill in Q4

He added, “The closing of the Oclaro acquisition in December gives us a first mover advantage in a consolidating industry and establishes leadership positions based on fundamental photonic chip capabilities across a broad range of products and technologies.”

The Milpitas, California-based company acquired optics firm Oclaro Inc in December, expecting an estimated $60 million in synergies in the 12-24 months. Under the terms of the merger agreement, Oclaro stockholders received $5.60 in cash and 0.0636 of a share of Lumentum common stock for each share of Oclaro common stock.

 

We’re on Apple News! Follow us to receive the latest stock market, earnings, and financial news at your fingertips

 

Most Popular

Intensity Therapeutics is establishing a new field of localized cancer reduction: CEO

Intensity Therapeutics, Inc. (NASDAQ: INTS) is a clinical biotechnology company engaged in the discovery development, and commercialization of first-in-class cancer drugs that attenuate tumors with minimal side effects while training

INTU Earnings: Intuit Q1 2025 adj. profit rises on higher revenues

Financial technology company Intuit Inc. (NASDAQ: INTU) Thursday announced results for the first quarter of 2025, reporting a modest increase in adjusted earnings. The Mountain View-headquartered company’s first-quarter revenue came

Riding the AI wave, Nvidia looks set to stay on the high-growth path

After delivering strong results for the third quarter, Nvidia Corporation (NASDAQ: NVDA) this week said the launch of its new-generation Blackwell chip is on track. The company is thriving on

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top